PHI with Infantile neuroaxonal dystrophy
How does this condition affect your private health insurance?
Dystrophie infantile neuroaxonale (INAD), or Infantile Neuroaxonal Dystrophy, is a rare, severe, and progressive neurodegenerative disorder affecting infants, typically appearing between 6 months and 3 years of age. It is characterized by the accumulation of spheroid bodies in the axons of nerve cells in the brain and spinal cord, caused by mutations in the PLA2G6 gene. Symptoms include progressive psychomotor regression, hypotonia, spasticity, visual impairment due to optic atrophy, and eventually loss of all acquired skills. Children with INAD experience severe neurological decline, leading to profound disability and premature death. There is currently no cure, and treatment is supportive, focusing on managing symptoms and improving quality of life.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Symptoms usually appear between 6 months and 3 years of age, with rapid progression over months.
Duration of Illness (Lifetime)
A progressive and fatal disease, typically leading to death by early childhood (often between 5-10 years of age) following several years of decline.
Cost of Treatment (Initial)
High. Initial diagnostic work-up (genetic testing, imaging) can cost thousands to tens of thousands of USD. Early supportive care adds to this.
Cost of Treatment (Lifetime)
Very high. Chronic palliative care, extensive physical and occupational therapies, respiratory support, feeding tubes, and specialized equipment can amount to hundreds of thousands to millions of USD.
Mortality Rate
100%. INAD is a uniformly fatal disease, usually by early to mid-childhood.
Risk of Secondary Damages
100%. Severe and progressive neurological damage, including profound developmental regression, spasticity, dystonia, optic atrophy, swallowing difficulties, respiratory insufficiency, and recurrent infections.
Probability of Full Recovery
0%. There is no cure for INAD, and the disease is relentlessly progressive.
Underlying Disease Risk
Low. INAD is a primary genetic disorder. However, complications like aspiration pneumonia or severe infections are common secondary issues.